A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that engraftment when administering cyclophosphamide post the stem cell
infusion will increase, the incidence of graft versus host disease (GVHD) and day 100
mortality will decrease, and the use of cyclophosphamide post stem cell infusion with
alternative donors will be as safe and as effective as traditional matched transplants.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University